Results 41 to 50 of about 4,638 (155)

“Influence of Clinically Active Graves’ Ophthalmopathy on Spherical Equivalent and Visual Acuity”

Clinical Ophthalmology, 2022
Jasenka Petrovic Jurcevic,1 Marko Jurcevic,2 Mateja Jagic,3 Anamarija Jazbec,4 Kresimir Mandic,5 Jelena Juri Mandic5 1Medical School University of Zagreb, PhD Candidate on the Programme “Biomedicine and Health”, Zagreb, Croatia; 2University of Zagreb ...
Petrovic Jurcevic J, Jurcevic M, Jagic M, Jazbec A, Mandic K, Juri Mandic J   +5 more
doaj  

Research progress on the pathogenesis of Graves’ ophthalmopathy: Based on immunity, noncoding RNA and exosomes

Frontiers in Immunology, 2022
Graves’ ophthalmopathy (GO), also known as thyroid-associated ophthalmopathy, is a common potentially vision-threatening organ-specific autoimmune disease and the most common extrathyroidal manifestation of Graves’ disease.
Jingyi Zheng, Jingyi Zheng, Honghong Duan, Sufang You, Sufang You, Bo Liang, Yuping Chen, Yuping Chen, Huibin Huang   +8 more
doaj   +1 more source

Early Low‐Dose Rituximab for Mild‐to‐Moderate Thyroid Eye Disease: A Preliminary Evaluation of Efficacy and Safety

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Background Thyroid eye disease (TED) is an autoimmune inflammatory condition linked to thyroid dysfunction, which can result in disfigurement and potential vision loss. Recently, immunomodulatory therapies such as rituximab have demonstrated potential benefit in managing TED.
Ming Lu, Luqiang Wang, Xuelian Zhang, Suraiya Saleem   +3 more
wiley   +1 more source

A Case of Euthyroid Graves’ Ophthalmopathy in a Patient Sero-Negative for TSH Receptor Autoantibody

Case Reports in Endocrinology, 2018
We report of a case of Graves’ ophthalmopathy presented solely with symptoms of the eyes with normal thyroid function tests and negative immunoreactive TSH receptor autoantibody.
Asami Hotta, Tomohiro Tanaka, Haruka Kato, Shota Kakoi, Yuki Shimizu, Chie Hasegawa, Akiko Hayakawa, Satoshi Yasuda, Kento Ogawa, Shunsuke Ito, Hideomi Ohguchi, Takashi Yagi, Hiroyuki Koyama, Mihoko Kawamura, Kazuhiko Sugitani, Yuichiro Ogura, Takashi Joh, Kenro Imaeda   +17 more
doaj   +1 more source

Factors Influencing the Conversion of Ocular Myasthenia Gravis to Generalized Myasthenia Gravis: A Retrospective Cohort Study

Journal of Ophthalmology, Volume 2026, Issue 1, 2026.
Purpose The conversion rate of ocular myasthenia gravis (OMG) to generalized myasthenia gravis (GMG) lacks definitive predictors. Methods This retrospective cohort study analyzed data collected at Siriraj Hospital between January 2007 and December 2019 to identify factors influencing OMG generalization and the time to conversion. The records of 200 OMG
Wanicha Chuenkongkaew, Niphon Chirapapaisan, Pawimon Chatchutimakorn, Natthapon Rattanathamsakul, Manassawee Joradoln, Pawita Kongthanasomboon, Akarawit Eiamsamarng, Gábor Tóth   +7 more
wiley   +1 more source

Hypothyroid Graves’ Ophthalmopathy: Report of Two Cases

Endocrinology Research and Practice, 2007
Graves’ disease is an autoimmune disorder of the thyroid gland. Ophthalmopathy is the most common peripheral manifestation of Graves’ disease. It is a very rare condition that a Graves’ patient presents with spontaneous hypothyroidism.
Barış Akıncı, Tevfik Demir, Abdurrahman Çömlekçi   +2 more
doaj   +2 more sources

Progress in the pathogenesis of thyroid-associated ophthalmopathy and new drug development

Taiwan Journal of Ophthalmology, 2020
Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (Graves' disease), also known as Graves' ophthalmopathy/orbitopathy. As an organ-specific autoimmune disease, the pathogenesis of TAO is still
Yazhuo Huang, Sijie Fang, Shuo Zhang, Huifang Zhou   +3 more
doaj   +1 more source

PDGFRα+DPP4+ Fibroblasts‐Macrophage Crosstalk Induces Orbital Fibrosis in Treatment‐Resistant Thyroid Eye Disease via the GAS6‐AXL Pathway

Advanced Science, Volume 12, Issue 45, December 4, 2025.
This study elucidates macrophage‐induced orbital fibrosis in TED via the GAS6‐AXL pathway, a treatment‐resistant disorder lacking non‐surgical therapies. Using a novel patient cell‐derived orthotopic animal model of orbital fibrosis for TED, we repurpose an existing fibrosis therapy, addressing the absence of stable models and offering a potential ...
Lu Cheng, Jinwei Cheng, Guiling Liang, Xiaorui Wang, Yanwen Ge, Jiapei Liu, Luwei Cai, Hui Ying, Fenfen Wang, Jing Hu, Yufan Wang, Philipp E. Scherer, Ben Zhou, Mengle Shao, Fang Zhang   +14 more
wiley   +1 more source

Immunological Aspects of Graves’ Ophthalmopathy [PDF]

BioMed Research International, 2019
The body’s autoimmune process is involved in the development of Graves’ disease (GD), which is manifested by an overactive thyroid gland. In some patients, autoreactive inflammatory reactions contribute to the development of symptoms such as thyroid ophthalmopathy, and the subsequent signs and symptoms are derived from the expansion of orbital adipose ...
Dominika Łacheta, Piotr Miśkiewicz, Alicja Głuszko, Grażyna Nowicka, Maria Struga, Ireneusz Kantor, Krzysztof B. Poślednik, Shafaq Mirza, Mirosław J. Szczepański   +8 more
openaire   +2 more sources

Pulse dexamethasone therapy versus pulse methylprednisolone therapy for treatment of Graves′s ophthalmopathy

Indian Journal of Endocrinology and Metabolism, 2013
Pulse methylprednisolone therapy is the recommended therapy for moderate to severe and active ophthalmopathy, but high dose pulse methylprednisolone therapy is marred by the chances of fulminant hepatic failure and the high cost of therapy. Dexamethasone
Rajeev Philip, Sanjay Saran, Manish Gutch, Pushpaltha Agroyia, Rajiv Tyagi, Keshavkumar Gupta   +5 more
doaj   +1 more source